What are the guidelines for initiating Tolvaptan (generic name) in an adult with autosomal dominant polycystic kidney disease who has an eGFR ≥30 mL/min/1.73 m², normal liver function and serum sodium, and is not pregnant or breastfeeding?

Guidelines for Initiating Tolvaptan in ADPKD Patients

Start tolvaptan at 45 mg upon waking and 15 mg eight hours later, titrating weekly to a target dose of 90 mg AM/30 mg PM, with mandatory monthly liver function monitoring for the first 18 months. 1

Patient Selection and Pre-Initiation Assessment

Before initiating tolvaptan, confirm the patient has rapidly progressive ADPKD (Mayo Imaging Classification 1C-1E or eGFR decline >3 mL/min/1.73 m²/year) 2. The 2025 KDIGO guidelines establish tolvaptan as the cornerstone therapy for patients at risk of rapid kidney disease progression 1.

Absolute Contraindications to Verify:

• Liver disease - Baseline hepatic impairment disqualifies patients due to hepatotoxicity risk 1
• Inability to sense or respond to thirst - Critical for managing aquaresis 1
• Concurrent strong CYP3A inhibitors (ketoconazole, clarithromycin, ritonavir) - Dramatically increase tolvaptan levels 1
• Pregnancy or breastfeeding - Tolvaptan may cause fetal harm 3
• Anuria - Drug requires urinary output 3

Pre-Treatment Counseling Requirements:

Patients must understand the aquaretic effect will cause marked polyuria and polydipsia. They need to:

• Drink water liberally throughout the day to replace urinary losses (typically >3L daily)
• Consume liquids without sugar or fat to minimize osmolar load 1
• Adopt low-sodium intake (<2000 mg/day) to reduce polyuria 1, 2
• Avoid grapefruit juice and moderate CYP3A inhibitors (diltiazem, verapamil, fluconazole, erythromycin) 1

Dosing Protocol

Initial Dosing:

• 45 mg upon waking
• 15 mg eight hours later (not at bedtime to minimize nocturia) 1

Titration Schedule:

After ≥1 week at each dose level 1:

Week	Morning Dose	Evening Dose
1+	45 mg	15 mg
2+	60 mg	30 mg
3+	90 mg	30 mg (target)

Continue tolvaptan until approaching kidney replacement therapy, even if eGFR falls below 25 mL/min/1.73 m² or patient age exceeds 55 years, provided it remains well-tolerated 1.

Critical Monitoring Requirements

Liver Function Tests (LFTs):

The most important safety concern is idiosyncratic drug-induced liver injury, occurring in approximately 5% of patients (vs 1% placebo) 1.

Mandatory monitoring schedule:

• Monthly for first 18 months
• Every 3 months thereafter until discontinuation 1
• Obtain morning blood samples before tolvaptan dose 1

LFT Management Algorithm:

If AST/ALT ≥3× ULN or >2× baseline (even if <2× ULN):

1. Hold tolvaptan immediately
2. Repeat LFTs within 48-72 hours
3. Assess for alternative etiologies (other drugs, viral hepatitis, alcohol)
4. If levels stable or improving AND alternative explanation found: May reinitiate with frequent monitoring
5. If levels ≥3× ULN without alternative explanation: Permanently discontinue 1

If multiple symptoms of liver injury (fatigue, nausea, vomiting, right upper quadrant pain, jaundice, pruritus):

• Hold tolvaptan immediately regardless of LFT values
• Urgent hepatology consultation 1

Additional Monitoring:

• Serum sodium - Provides insight into adequacy of water intake; morning samples before tolvaptan dose 1
• Serum potassium - If baseline >5 mEq/L or on ACE inhibitors/ARBs/potassium-sparing diuretics 3
• eGFR - Expect small, reversible initial decline reflecting reduced hyperfiltration 1

"Sick Day Plan" - Critical Safety Measure

Patients must skip tolvaptan doses during situations risking volume depletion 1:

• Acute illness with vomiting/diarrhea
• Limited access to water (travel, outdoor activities)
• Hot weather with increased insensible losses
• Inability to drink adequately for any reason

This is non-negotiable to prevent dangerous dehydration and acute kidney injury.

Dose Adjustments and Special Situations

Consider Downtitration or Holding:

• Concurrent moderate CYP3A inhibitors (amiodarone, diltiazem, verapamil, fluconazole, erythromycin) 1
• Intolerance or aquaretic side effects
• Elevated liver enzymes (see algorithm above) 1

Expected Initial eGFR Changes:

Tolvaptan causes a small, reversible eGFR reduction early in treatment, reflecting decreased compensatory hyperfiltration rather than true kidney injury 1. This should not prompt discontinuation unless accompanied by volume depletion.

Evidence Supporting This Approach

The TEMPO 3:4 and REPRISE trials demonstrated tolvaptan slows eGFR decline by 1.3 mL/min/1.73 m²/year and reduces total kidney volume growth by 2.7% compared to placebo 1. Additionally, tolvaptan significantly reduced UTIs, kidney stones, hematuria, and kidney pain events 1. These benefits in preserving kidney function and reducing morbidity justify the aquaretic side effects and monitoring burden in appropriately selected patients.

Common pitfall: Providers sometimes hesitate to uptitrate due to patient complaints of polyuria. However, the target dose of 90/30 mg provides maximal benefit, and patients typically adapt to aquaresis within weeks with proper counseling and hydration strategies.